Is Cinacalcet Useful in Dialysis Patients?
Berns on Nephrology video blog from Medscape Nephrology.
Editor's note: In January 2013, The New York Times reported that Congress included a delay of Medicare price restraints on Sensipar/cinacalcet (made by Amgen) until 2016 in the 'fiscal cliff' legislation. See articles from NN&I, Ventura County Star, and The Hill.
In response to this criticism, Amgen provided a press release on Feb. 22, 2013 stating that a Congressional Budget Office (CBO) analysis released that week showed that keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for both taxpayers and the Medicare program. However, where did this analysis go? It now does not appear in the Amgen press release, nor in the CBO listing for February 2013, nor in this Huffington Post story based on the CBO analysis.
In March 2014,
Amgen was able to insert a provision into rushed legislation (121-page pdf) that delayed Medicare price restraints on Sensipar/cinacalet until 2024. AP article quote:
"It also contains a provision benefiting, among others, Amgen Inc., which produces an oral drug for kidney dialysis patients. It would extend through 2024 a controversial provision to allow payments for Sensipar, which is made by Amgen, to be made on top of other "bundled" payments made to treat Medicare patients with kidney disease. It also eases cuts to dialysis providers who have battled with drug companies over the issue."